Health Care·Pharmaceuticals·$2.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.08 | N/A | -8.24% |
management commentary, guidance changes, and full analysis available with Pro.
| -8.24% |
Tone: Defensive
Overall, management expressed concern about market conditions impacting performance. They highlighted a commitment to improving operational metrics.
Management acknowledged challenges in the current market environment.
They emphasized a focus on operational efficiency moving forward.
The earnings report indicates that Organon & Co faced challenges, resulting in an EPS miss. The stock reacted negatively, dropping 9.2%, likely due to investor concerns about ongoing market pressures and the lack of updated guidance from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
May 1, 2023